Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977912 | 0.79 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1TAAR1PKM | |
| SCHEMBL14401056 | 0.78 | MITF (0.40) | ALDH1A1LMNAPKMMAPTNPSR1 | |
| SCHEMBL6173265 | 0.77 | ADA (0.59) | ALDH1A1KMT2AMEN1LMNAOPRM1 | |
| SCHEMBL6385922 | 0.76 | SOS1 (0.41) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL14400982 | 0.76 | GAA (0.47) | ALDH1A1KMT2AMEN1LMNACYP2C9 | |
| SCHEMBL18516673 | 0.74 | ADA (0.46) | ALDH1A1KMT2AMEN1LMNATAAR1 | |
| SCHEMBL9146622 | 0.74 | PKM (0.39) | ALDH1A1KMT2AMEN1TAAR1PKM | |
| SCHEMBL21198912 | 0.71 | PKM (0.37) | ALDH1A1KMT2AMEN1TAAR1PKM | |
| SCHEMBL9327812 | 0.70 | CYP26A1 (0.58) | ALDH1A1KMT2AMEN1LMNAOPRK1 | |
| SCHEMBL2983258 | 0.70 | BCHE (0.37) | ALDH1A1KMT2AMEN1LMNATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| CN-101282941-A | Imidazole compounds for the treatment of neurological disorders | PFIZER (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1940802-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pfizer Products Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034326-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | ALDH1A1 807/4885KMT2A 2322/4885MEN1 485/4885 |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | APP, PSEN1, BACE1 | ALDH1A1 807/4885KMT2A 2322/4885MEN1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.